Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration ...

Natera reported gross margin of just under 65% in Q1, above the company’s prior midpoint expectation of 64% for full-year 2026. Chapman said rapid volume growth created a roughly 2 percentage point ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual ...

Natera Inc. NTRA shares are up on Tuesday as the company announced promising results from a prospective study regarding its Signatera molecular residual disease (MRD) test. • Natera stock is showing ...

Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, ...

Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant ...

Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for MRD-positive patients while sparing MRD-negative patients from ...

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Testicular cancer represents approximately 95% of all GCTs 1 and is the most ...

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision ...